Biodesix Consensus Price Target Raised by 12.20% to $37.54
The average one-year price target for Biodesix (NASDAQGM:BDSX) has been revised to $37.54 / share. This is an increase of 12.20% from the prior estimate of $33.46 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute an investment recommendation by Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $30.30 to a high of $43.05 / share. The average price target represents an increase of 37.34% from the closing price of $27.33 / share reported on October 1, 2026.
As of September 29, 2026, the median price target increased to $38.76 from a prior median of $32.64, representing an absolute median change of $6.12. The target range narrowed by -13.44%, with the current target range width at $12.75 compared to the prior width of $14.73. Looking at the target history, the mean target was $37.54 on October 2, 2026, up from $33.46 on September 15, 2026, and August 28, 2026, and $29.32 on August 4, 2026. This represents a target change of +28.00% since the 90-day baseline date of July 1, 2026. The observed twelve-month high mean target is $37.54, recorded on October 2, 2026, while the observed twelve-month low mean target is $26.52, recorded on June 8, 2026.
In terms of price performance, Biodesix experienced a one-week price change of -7.04% relative to a baseline close of $29.40 on September 24, 2026, and a one-month price change of +9.01% relative to a baseline close of $25.07 on September 1, 2026. The company's latest earnings report on August 5, 2026, showed an actual EPS of -0.71, compared to the estimated EPS of -0.9203. Actual revenue was $26,861,000.00, which was a +1.19% surprise over the estimated revenue of $26,546,224.00.
Analyst sentiment remains steady. As of September 1, 2026, the recommendation breakdown consists of 3 strong buy, 9 buy, and 1 hold ratings, representing 92.3% positive recommendations and 7.7% hold recommendations. This distribution is unchanged from the prior recommendation period of August 1, 2026. In the broader Diversified Financial Services sub-industry, which covers 16 companies, 2 companies saw target raises, 2 saw target decreases, and 12 remained unchanged, with a median revision percent of 0.00% and a median implied change percent of +37.34%.
Several peers in the diagnostics and precision oncology space also saw revisions to their targets. Guardant Health, Natera, and Veracyte serve as comparable companies. Among these peers, both Guardant Health and Natera saw upward target revisions, while Veracyte's target remained unchanged.
| Company name | Target revision | Implied change |
|---|---|---|
| Guardant Health | +2.07% | +14.71% |
| Natera | +3.01% | -15.14% |
| Veracyte | 0.00% | +34.84% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.